- Home
- CURB vs IOVA Comparison
CURB vs IOVA Comparison
Compare CURB & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURB
- IOVA
- Stock Information
- Founded
- CURB 2024
- IOVA 2007
- Country
- CURB United States
- IOVA United States
- Employees
- CURB N/A
- IOVA N/A
- Industry
- CURB
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CURB
- IOVA Health Care
- Exchange
- CURB NYSE
- IOVA Nasdaq
- Market Cap
- CURB N/A
- IOVA 1.0B
- IPO Year
- CURB N/A
- IOVA N/A
- Fundamental
- Price
- CURB $23.28
- IOVA $3.51
- Analyst Decision
- CURB Buy
- IOVA Strong Buy
- Analyst Count
- CURB 7
- IOVA 9
- Target Price
- CURB $26.29
- IOVA $18.22
- AVG Volume (30 Days)
- CURB 844.1K
- IOVA 10.2M
- Earning Date
- CURB 04-24-2025
- IOVA 05-08-2025
- Dividend Yield
- CURB 1.76%
- IOVA N/A
- EPS Growth
- CURB N/A
- IOVA N/A
- EPS
- CURB 0.11
- IOVA N/A
- Revenue
- CURB $131,537,000.00
- IOVA $164,070,000.00
- Revenue This Year
- CURB $24.92
- IOVA $182.20
- Revenue Next Year
- CURB $16.33
- IOVA $62.10
- P/E Ratio
- CURB $211.40
- IOVA N/A
- Revenue Growth
- CURB 31.90
- IOVA 13698.99
- 52 Week Low
- CURB $18.80
- IOVA $2.70
- 52 Week High
- CURB $25.69
- IOVA $14.23
- Technical
- Relative Strength Index (RSI)
- CURB N/A
- IOVA 51.94
- Support Level
- CURB N/A
- IOVA $2.89
- Resistance Level
- CURB N/A
- IOVA $3.43
- Average True Range (ATR)
- CURB 0.00
- IOVA 0.32
- MACD
- CURB 0.00
- IOVA 0.09
- Stochastic Oscillator
- CURB 0.00
- IOVA 86.17
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.